Results from a systematic programme of evaluating COVID-19 reinfection cases in the early phase of the pandemic, Singapore.
COVID-19
Reinfection
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
14 Feb 2023
14 Feb 2023
Historique:
received:
28
09
2022
accepted:
06
02
2023
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
The objectives of this study were to describe the coronavirus disease caused by SARS-CoV-2 (COVID-19) reinfection evaluation algorithm used in the early phase of the pandemic in Singapore and analyze the clinical and laboratory characteristics of the cases evaluated. We performed a retrospective case-control analysis including all COVID-19 cases evaluated for possible reinfection under the local COVID-19 reinfection evaluation programme between 1 June 2020-30 June 2021. Whole genome sequencing (WGS) was used as confirmatory testing. We compared all reinfection ("RI") cases against those who were evaluated but eventually assessed not to be reinfection ("non-RI"). There were 74 possible reinfection cases evaluated through the programme, of which 32 were subsequently classified as RI. There was strong statistical evidence that RI cases had a longer interval between 1st and 2nd episode (mean 297 days; 95%-confidence interval (CI) 267-327) compared to non-RI cases (mean 186 days; 95%-CI 144-228). The cycle threshold (Ct) value of initial polymerase chain rection (PCR) at 2nd episode was also found to be significantly lower in RI cases (mean 23; 95%-CI 20-26) compared to non-RI cases (mean 34; 95%-CI 32-36). There was no significant difference in the proportion of individuals who had fever, acute respiratory symptoms or asymptomatic in both groups. Delta and beta variants were most commonly identified from WGS and provide indication of re-infection as these were not 'wild-type' and were not circulating during the time period of the index infection. Using a combination of serologic, microbiologic and genomic criteria to evaluate possible reinfection cases is useful and can provide a framework for evaluation that may be modified for future similar situations.
Identifiants
pubmed: 36788516
doi: 10.1186/s12879-023-08056-8
pii: 10.1186/s12879-023-08056-8
pmc: PMC9927039
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Informations de copyright
© 2023. The Author(s).
Références
Occup Environ Med. 2020 Sep;77(9):634-636
pubmed: 32513832
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
PLoS One. 2021 May 4;16(5):e0251214
pubmed: 33945583
Int J Environ Res Public Health. 2020 Dec 31;18(1):
pubmed: 33396275
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Diabetes Metab Syndr. 2021 Mar-Apr;15(2):645-648
pubmed: 33663969
J Investig Med. 2021 Aug;69(6):1253-1255
pubmed: 34006572
Emerg Infect Dis. 2020 Dec;26(12):3076-3078
pubmed: 33089772
Open Forum Infect Dis. 2021 Nov 03;9(1):ofab549
pubmed: 35024370
Clin Microbiol Infect. 2021 Mar;27(3):315-318
pubmed: 33285276
Clin Infect Dis. 2021 Nov 2;73(9):e2932-e2942
pubmed: 32856707